Aron Jaffe
@jaffeab.bsky.social
SVP @ https://curie.bio/; Former SVP Head of Research @chromamedicine; EIR @ThirdRockV; Reg Med, uBiome group leader/Resp DA co-lead @NovartisScience. Opinions my own.
Pinned
Aron Jaffe
@jaffeab.bsky.social
· Dec 9
Curie.Bio
Curie.Bio is a new model for venture capital in biotech. We are focused on a singular mission – helping founders launch therapeutics companies that go on to raise an awesome next round of financing.
curie.bio
Excited to continue my passion for translating cutting edge technologies & biological insights into new therapeutic approaches to disease as part of the team at curie.bio starting TODAY!
Feels like the first day of school, except I don’t have to bring my own snacks...
Feels like the first day of school, except I don’t have to bring my own snacks...
What if RFK Jr. reacted to his cousin’s terminal cancer as JFK reacted to his baby’s death? www.statnews.com/2025/11/26/t... via @statnews.com
What if RFK Jr. reacted to his cousin’s terminal cancer as JFK reacted to his baby’s death?
When President Kennedy’s newborn son died in 1963, it galvanized research. A new Kennedy family tragedy should spur RFK Jr. to support cancer research, not cut it.
www.statnews.com
November 27, 2025 at 12:10 PM
What if RFK Jr. reacted to his cousin’s terminal cancer as JFK reacted to his baby’s death? www.statnews.com/2025/11/26/t... via @statnews.com
Congratulations to Mike Welsh @iowamed.bsky.social, Paul Negulescu @vertexpharm.bsky.social, & Jesus Gonzalez
on their well-deserved award. If you're not familiar with the path to CFTR therapies, it's worth a read.
laskerfoundation.org/winners/comb...
on their well-deserved award. If you're not familiar with the path to CFTR therapies, it's worth a read.
laskerfoundation.org/winners/comb...
Triple-drug therapy for cystic fibrosis - Lasker Foundation
Jesús (Tito) González, Paul A. Negulescu, Michael J. Welsh
laskerfoundation.org
September 11, 2025 at 2:26 PM
Congratulations to Mike Welsh @iowamed.bsky.social, Paul Negulescu @vertexpharm.bsky.social, & Jesus Gonzalez
on their well-deserved award. If you're not familiar with the path to CFTR therapies, it's worth a read.
laskerfoundation.org/winners/comb...
on their well-deserved award. If you're not familiar with the path to CFTR therapies, it's worth a read.
laskerfoundation.org/winners/comb...
Reassessment of antibody-based detection of the murine T cell GLP-1 receptor
cell.com/cell-metabol...
'Our findings reveal caveats governing use of multiple widely used GLP-1R antibodies, reemphasizing the importance of rigorous antibody validation'
Thanks @danieljdrucker.bsky.social & team
cell.com/cell-metabol...
'Our findings reveal caveats governing use of multiple widely used GLP-1R antibodies, reemphasizing the importance of rigorous antibody validation'
Thanks @danieljdrucker.bsky.social & team
Reassessment of antibody-based detection of the murine T cell GLP-1 receptor
Glucagon-like peptide 1 receptor (GLP-1R) agonists exhibit anti-inflammatory actions,
yet the importance of direct immune cell GLP-1R signaling remains uncertain. Although
T cells respond to GLP-1, lo...
cell.com
September 8, 2025 at 11:41 AM
Reassessment of antibody-based detection of the murine T cell GLP-1 receptor
cell.com/cell-metabol...
'Our findings reveal caveats governing use of multiple widely used GLP-1R antibodies, reemphasizing the importance of rigorous antibody validation'
Thanks @danieljdrucker.bsky.social & team
cell.com/cell-metabol...
'Our findings reveal caveats governing use of multiple widely used GLP-1R antibodies, reemphasizing the importance of rigorous antibody validation'
Thanks @danieljdrucker.bsky.social & team
I inserted myself into a conversation at a bar about Covid and vaccines. Here’s what happened www.statnews.com/2025/09/06/c... via @statnews.com
I inserted myself into a conversation at a bar about Covid and vaccines. Here’s what happened
What happened when a public health scientist overheard four men sharing misinformation about Covid — and decided to talk to them about it.
www.statnews.com
September 7, 2025 at 1:08 PM
I inserted myself into a conversation at a bar about Covid and vaccines. Here’s what happened www.statnews.com/2025/09/06/c... via @statnews.com
When a therapeutic approach works, it's on us as a global community to figure out how to get it to ALL patients in need. Great piece by @jasonmast.bsky.social
What Baby KJ means for the CRISPR gene editing industry www.statnews.com/2025/05/26/w... via @statnews.com
What Baby KJ means for the CRISPR gene editing industry www.statnews.com/2025/05/26/w... via @statnews.com
What Baby KJ means for the CRISPR gene editing industry
The custom-built gene editing treatment for 6-month-old KJ Muldoon could not have come at a more welcome or jarring time for CRISPR-powered biomedicine.
www.statnews.com
May 27, 2025 at 1:20 PM
When a therapeutic approach works, it's on us as a global community to figure out how to get it to ALL patients in need. Great piece by @jasonmast.bsky.social
What Baby KJ means for the CRISPR gene editing industry www.statnews.com/2025/05/26/w... via @statnews.com
What Baby KJ means for the CRISPR gene editing industry www.statnews.com/2025/05/26/w... via @statnews.com
FDA delays are bad in general, but for a small biotech they can be existential. Let’s hope this is an edge case.
endpts.com/fda-delays-s...
endpts.com/fda-delays-s...
FDA delays PDUFA date for small biotech, raising questions about impact of agency cuts
The fate of a small, privately-held biotech’s new drug has been delayed, in what appears to be a sign that broad cuts to the FDA by the Trump administration may ...
endpts.com
April 29, 2025 at 11:02 AM
FDA delays are bad in general, but for a small biotech they can be existential. Let’s hope this is an edge case.
endpts.com/fda-delays-s...
endpts.com/fda-delays-s...
Congrats to Sek Kathiresan and the entire Verve Therapeutics team.
Big day for the field. Bigger day for patients.
www.globenewswire.com/news-release...
Big day for the field. Bigger day for patients.
www.globenewswire.com/news-release...
Verve Therapeutics Announces Positive Initial Data from the Heart-2 Phase 1b Clinical Trial of VERVE-102, an In Vivo Base Editing Medicine Targeting PCSK9
Single infusion of VERVE-102 led to dose-dependent decreases in blood PCSK9 and LDL-C, with mean reduction in LDL-C of 53% and a maximum reduction of 69%...
www.globenewswire.com
April 15, 2025 at 1:04 PM
Congrats to Sek Kathiresan and the entire Verve Therapeutics team.
Big day for the field. Bigger day for patients.
www.globenewswire.com/news-release...
Big day for the field. Bigger day for patients.
www.globenewswire.com/news-release...
First game of the season with the boy. Never gets old.
April 6, 2025 at 6:13 PM
First game of the season with the boy. Never gets old.
Reposted by Aron Jaffe
Tempero Bio raises $70M for TMP-301, a daily pill in development for alcohol and cocaine use disorders. Phase 2 data expected in 2026.
endpts.com/tempero-bio-...
endpts.com/tempero-bio-...
Tempero Bio, led by ex-Novartis execs, gets $70M to reduce substance use disorders
A small Oakland, CA-based biotech hoping to take on the sprawling landscape of substance use disorders and addiction has reeled in $70 million. The drug development startup, named Tempero Bio ...
endpts.com
March 24, 2025 at 7:38 PM
Tempero Bio raises $70M for TMP-301, a daily pill in development for alcohol and cocaine use disorders. Phase 2 data expected in 2026.
endpts.com/tempero-bio-...
endpts.com/tempero-bio-...
This is a big day for patients with AATD and a big win for genomic medicine. Congrats to the entire Beam Team @BeamTx!
investors.beamtx.com/news-release...
investors.beamtx.com/news-release...
Beam Therapeutics Announces Positive Initial Data for BEAM-302 in the Phase 1/2 Trial in Alpha-1 Antitrypsin Deficiency (AATD), Demonstrating First Ever Clinical Genetic Correction of a Disease-causin...
Single Dose of BEAM-302 Led to Durable, Dose-dependent Increases in Total and Functional Alpha-1 Antitrypsin (AAT), Production of Corrected M-AAT, and Decreases in Mutant Z-AAT in Circulation Across I...
investors.beamtx.com
March 10, 2025 at 10:12 PM
This is a big day for patients with AATD and a big win for genomic medicine. Congrats to the entire Beam Team @BeamTx!
investors.beamtx.com/news-release...
investors.beamtx.com/news-release...
This 💯
Cod liver oil? Nothing against it if you don't have Vitamin A, but better yet, get vaccinated--prevents the child from getting sick in the first place, so we don't need to assist with ambulances! AAP and ISDA websites have all the data and answers to questions.
www.nytimes.com/2025/03/04/h...
www.nytimes.com/2025/03/04/h...
As Measles Spreads, Kennedy Embraces Remedies Like Cod Liver Oil
In an interview, the H.H.S. secretary claimed that unconventional treatments were helping patients but did not mention vaccination.
www.nytimes.com
March 6, 2025 at 6:20 PM
This 💯
Congratulations to Stefan Irion, Seth Ettenberg, and the entire Blue Rock team!
BlueRock Therapeutics receives FDA Fast Track Designation for OpCT-001 for the treatment of primary photoreceptor diseases
www.bluerocktx.com/bluerock-the...
BlueRock Therapeutics receives FDA Fast Track Designation for OpCT-001 for the treatment of primary photoreceptor diseases
www.bluerocktx.com/bluerock-the...
BlueRock Therapeutics receives FDA Fast Track Designation for OpCT-001 for the treatment of primary photoreceptor diseases - BlueRock Therapeutics LP
The U.S. Food and Drug Administration (FDA) has granted Fast Track designation for OpCT-001, an investigational induced pluripotent stem cell (iPSC)-derived cell therapy for the treatment of primary p...
www.bluerocktx.com
February 27, 2025 at 2:38 PM
Congratulations to Stefan Irion, Seth Ettenberg, and the entire Blue Rock team!
BlueRock Therapeutics receives FDA Fast Track Designation for OpCT-001 for the treatment of primary photoreceptor diseases
www.bluerocktx.com/bluerock-the...
BlueRock Therapeutics receives FDA Fast Track Designation for OpCT-001 for the treatment of primary photoreceptor diseases
www.bluerocktx.com/bluerock-the...
Reposted by Aron Jaffe
The flu, meanwhile, has been going from mild to wild in recent weeks.
February 16, 2025 at 5:43 PM
The flu, meanwhile, has been going from mild to wild in recent weeks.
Reposted by Aron Jaffe
Most genome editing work to date has been DNA based. A new paper out today assessed a single dose of epigenetic editing (thru PCSK9) for marked (~70%) and durable reduction of LDL cholesterol [in non-human primates]
www.nature.com/articles/s41...
www.nature.com/articles/s41...
A potent epigenetic editor targeting human PCSK9 for durable reduction of low-density lipoprotein cholesterol levels - Nature Medicine
Epigenetic editing of PCSK9 in the liver, designed to induce DNA methylation and silence gene expression, achieved long-lasting reductions in LDL cholesterol levels in both transgenic mice expressing ...
www.nature.com
February 10, 2025 at 4:01 PM
Most genome editing work to date has been DNA based. A new paper out today assessed a single dose of epigenetic editing (thru PCSK9) for marked (~70%) and durable reduction of LDL cholesterol [in non-human primates]
www.nature.com/articles/s41...
www.nature.com/articles/s41...
Our work describing the development of a potent epigenetic editor targeting human #PCSK9 for durable reduction of LDL-C is out in @naturemedicine.bsky.social today!
Cc: @chromamedicine @nchromabio
1/9
www.nature.com/articles/s41...
Cc: @chromamedicine @nchromabio
1/9
www.nature.com/articles/s41...
A potent epigenetic editor targeting human PCSK9 for durable reduction of low-density lipoprotein cholesterol levels - Nature Medicine
Epigenetic editing of PCSK9 in the liver, designed to induce DNA methylation and silence gene expression, achieved long-lasting reductions in LDL cholesterol levels in both transgenic mice expressing ...
www.nature.com
February 10, 2025 at 2:05 PM
Our work describing the development of a potent epigenetic editor targeting human #PCSK9 for durable reduction of LDL-C is out in @naturemedicine.bsky.social today!
Cc: @chromamedicine @nchromabio
1/9
www.nature.com/articles/s41...
Cc: @chromamedicine @nchromabio
1/9
www.nature.com/articles/s41...
As usual, @lisamjarvis.bsky.social absolutely nailing it.
🧪 About that "gold standard science" RFK is promising...and other takeaways from his two days in the hot seat. My latest @opinion.bloomberg.com (gift link):
RFK Jr. Is Not Up to the Enormous Task Before Him
During his confirmation hearings, President Trump’s nominee to lead the Department of Health and Human Services showed that his dangerous views on vaccines and science haven’t changed.
www.bloomberg.com
February 1, 2025 at 3:04 PM
As usual, @lisamjarvis.bsky.social absolutely nailing it.
iPSC-derived cardiomyocytes + stromal cells = engineered heart muscle
Science is truly amazing
www.nature.com/articles/s41...
Science is truly amazing
www.nature.com/articles/s41...
Engineered heart muscle allografts for heart repair in primates and humans - Nature
Epicardial engineered heart muscle allografts from induced pluripotent stem cell-derived cardiomyocytes can safely and effectively remuscularize chronically failing hearts in rhesus macaques, leading ...
www.nature.com
January 30, 2025 at 4:27 PM
iPSC-derived cardiomyocytes + stromal cells = engineered heart muscle
Science is truly amazing
www.nature.com/articles/s41...
Science is truly amazing
www.nature.com/articles/s41...
💯👇🏼
‘These founders have this idea, and for $10 million we can literally go from what those founders had to a development candidate…. It’s extraordinarily exciting’
www.statnews.com/2025/01/29/c...
‘These founders have this idea, and for $10 million we can literally go from what those founders had to a development candidate…. It’s extraordinarily exciting’
www.statnews.com/2025/01/29/c...
Biotech accelerator Curie.Bio raises $340 million for a new seed fund
Curie.Bio, the biotech accelerator and investment firm, has raised another $340 million to invest in startups.
www.statnews.com
January 29, 2025 at 5:43 PM
💯👇🏼
‘These founders have this idea, and for $10 million we can literally go from what those founders had to a development candidate…. It’s extraordinarily exciting’
www.statnews.com/2025/01/29/c...
‘These founders have this idea, and for $10 million we can literally go from what those founders had to a development candidate…. It’s extraordinarily exciting’
www.statnews.com/2025/01/29/c...
Congrats to Seth Ettenberg, Stefan Irion, and the entire Blue Rock team. #Parkinsons patients are waiting.
www.bayer.com/media/en-us/...
www.bayer.com/media/en-us/...
www.bayer.com
January 13, 2025 at 2:05 PM
Congrats to Seth Ettenberg, Stefan Irion, and the entire Blue Rock team. #Parkinsons patients are waiting.
www.bayer.com/media/en-us/...
www.bayer.com/media/en-us/...